Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study

Burger, Andrew J.; Horton, Darlene P.; LeJemtel, Thierry H.; Ghali, Jalal K.; Torre, Guillermo; Dennish, George W.; Koren, Michael; Dinerman, Jay L.; Silver, Marc A.; Cheng, Ming; Elkayam, Uri

doi:10.1067/mhj.2002.125620

Cited by 295 publications

(183 citation statements)

References 20 publications

Supporting

Mentioning

172

Contrasting

Unclassified

Order By: Relevance

“…Ventricular tachycardia occurred in 13% of dobutamine patients, compared with 6% of those treated with nesiritide, in whom ventricular ectopic beats actually decreased. 76 Together, these studies indicate that a noninotrope with the same vasoactive properties as an inotrope is equally efficacious and less toxic.…”

Section: Inotropic Therapy In Human Heart Failurementioning

confidence: 88%

Manipulating Cardiac Contractility in Heart Failure

2004

View full text Add to dashboard Cite

Section: Inotropic Therapy In Human Heart Failurementioning

confidence: 88%

Manipulating Cardiac Contractility in Heart Failure

2004

View full text Add to dashboard Cite

“…Nevertheless, it is still unavailable in Latin America. The studies have shown a greater reduction in pulmonary capillary pressure when compared to nitroglycerin [92][93][94][95] , with no increase of baseline heart rate and with no proarrhythmic effect 94 . A non-blind study suggested that nesiritide can reduce costs and mortality when compared with dobutamine 96 .…”

Section: Nesiritidementioning

confidence: 99%

I Diretriz Latino-Americana para avaliação e conduta na insuficiência cardíaca descompensada

Bocchi¹,

Vilas-Boas²,

Perrone³

et al. 2005

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

“…2 Nesiritide was approved in 2001 by the United States Food and Drug Administration and is indicated for intravenous treatment of patients with ADHF who have dyspnea at rest or with minimal activity. [13][14][15][16] The effects of nesiritide on discharge status, length of stay (LOS), total inpatient health care costs, and readmission rates are not fully determined. A recent meta-analysis suggests that nesiritide may have an adverse effect on mortality.…”

mentioning

confidence: 99%

Outcomes Associated with Vasoactive Therapy in Patients with Acute Decompensated Heart Failure

et al. 2006

View full text Add to dashboard Cite

Study Objectives. To describe the clinical management of acute decompensated heart failure (ADHF) in patients receiving intravenous treatment with dobutamine, milrinone, or nesiritide, and to evaluate differences, based on treatment received, in the in-hospital mortality rate, length of stay (LOS), total health care costs, and 30-day hospital readmission rate. according to the vasoactive therapy received. To evaluate baseline characteristics, 2 analysis was used; logistic regression was employed to assess the relationships between drug therapy and in-hospital mortality rates, and multivariate linear regression was used to assess whether drug therapy was related to LOS and total health care costs. All regression analyses controlled for age, sex, race, region of the United States where the hospital was located, primary payer for the hospital stay, UHC patient severity class, and chronic renal failure. In-hospital mortality rates were 10.2%, 7.9%, and 2.9% in the dobutamine, milrinone, and nesiritide groups, respectively. This resulted in an adjusted odds ratio for death of 3.5 (95% confidence interval [CI] 1.8-6.8) for dobutamine and 3.9 (95% CI 1.8-8.3) for milrinone (p<0.0001). Compared with inotropic therapy (dobutamine and milrinone), mean LOS in the hospital and the intensive care unit were lower with nesiritide (p<0.001). Total health care costs were lowest with nesiritide, but this reached statistical significance only when compared with milrinone (p<0.001). Thirty-day hospital readmission rates with dobutamine, milrinone, and nesiritide were 5.0%, 9.5%, and 3.9%, respectively (p=NS). Conclusion. Nesiritide therapy was associated with a lower in-hospital mortality rate and shorter LOS compared with dobutamine and milrinone. In addition, total health care costs with nesiritide were decreased compared with milrinone. These observations need to be validated by a randomized controlled trial.

show abstract

Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study

Cited by 295 publications

References 20 publications

Manipulating Cardiac Contractility in Heart Failure

Manipulating Cardiac Contractility in Heart Failure

I Diretriz Latino-Americana para avaliação e conduta na insuficiência cardíaca descompensada

Outcomes Associated with Vasoactive Therapy in Patients with Acute Decompensated Heart Failure

Contact Info

Product

Resources

About